Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vyant Bio Inc (VYNT)

Vyant Bio Inc (VYNT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vyant Bio Inc 2 Executive Campus 2370 State Route 70 West Suite 310 Cherry Hill NJ 08002 USA

www.vyantbio.com P: 201-479-1357

Description:

VYANT BIO INC. operates through wholly-owned subsidiaries, StemoniX and vivoPharm. StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. VYANT BIO INC., formerly known as Cancer Genetics Inc., is based in CHERRY HILL, N.J.

Key Statistics

Overview:

Market Capitalization, $K 1,228
Enterprise Value, $K -8,752
Shares Outstanding, K 6,329
Annual Sales, $ 670 K
Annual Net Income, $ -22,690 K
Last Quarter Sales, $ 120 K
Last Quarter Net Income, $ -1,630 K
EBIT, $ -13,250 K
EBITDA, $ -12,410 K
60-Month Beta 1.68
% of Insider Shareholders 9.56%
% of Institutional Shareholders 0.00%
Float, K 5,724
% Float 90.44%
Short Volume Ratio 0.06

Growth:

1-Year Return -72.29%
3-Year Return -98.60%
5-Year Return -99.71%
5-Year Revenue Growth -97.70%
5-Year Earnings Growth 100.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 01/02/24
Earnings Per Share ttm -0.62
EPS Growth vs. Prev Year -78.46%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 11/02/22

VYNT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -151.82%
Return-on-Assets % -97.14%
Profit Margin % -3,386.57%
Debt/Equity 0.01
Price/Sales 1.71
Price/Cash Flow N/A
Price/Book 0.27
Book Value/Share 0.71
Interest Coverage -176.67
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar